Press releases
Jens Eckstein named President of SR One, GSK’s venture healthcare group
Jens Eckstein has been named President of SR One, GSK’s independent healthcare venture organisation, effective 1 October. Jens will report to R&D Chairman Moncef Slaoui and be based in Boston. He replaces Christoph Westphal, who will be leaving GSK at the end of the year to focus on external business interests, including the Longwood Founder’s Fund, in which GSK is an investor.
GlaxoSmithKline (GSK) shows sign of things to come at London 2012 Olympic and Paralympic Games
2012 provider, GSK, unveils sign celebrating its scientific contribution to the Games
GSK awarded contract by BARDA to support research on potential novel antibiotic
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens.
GSK takes minority stake in new spin out Autifony Therapeutics
GlaxoSmithKline plc today announced that its wholly-owned subsidiary Glaxo Group Limited (GSK) will receive a 25.4% minority equity stake, representing a £1,250,000 investment, in Autifony Therapeutics Limited, a UK-based biotechnology start up created through a funding round of up to £10 million alongside investors Imperial Innovations and SV Life Sciences.
GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease
- IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of “off time” during waking hours
GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform
GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed agreements for the supply and commercialisation on an exclusive basis of the Enigma® ML system in Europe and other designated key countries, including India, Brazil and Russia. The agreements include development by Enigma of an initial range of respiratory tests for use on its real-time Polymerase Chain Reaction (PCR) technology platform, and provide GSK the opportunity to generate revenues from further test developments in infectious diseases and in other therapeutic areas relevant to its healthcare business.
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
GlaxoSmithKline (NYSE and LSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting approval of Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults. The sNDA has been submitted to the FDA by GSK.
Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam
Stiefel, a GSK company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12 years of age or older.
GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Full details of GSK's results for the second quarter of 2011 can be found in the
GlaxoSmithKline European regulatory update on Pandemrix™
GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to the product label for the H1N1 influenza vaccine, Pandemrix.
